CCCarmen Jia Yinn Chang

Carmen Jia Yinn Chang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carmen Jia Yinn Chang has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Repetitive transcranial magnetic stimulation as adjunctive therapy in adult patients with drug‐resistant epilepsy—A systematic review and meta‐analysis

    by Marjorie Jia Yi Ong, Muhammad Samir Haziq Abd Rahman, Carmen Jia Yinn Chang, Zhi Wen Wong, Wen Hui Wee, Ching Soong Khoo, Hui Jan Tan, Azman Ali Raymond, Antonio Valentin, Eugen Trinka, et al.

    Purpose: We performed a comprehensive systematic review and meta‐analysis of repetitive transcranial magnetic stimulation (rTMS) to explore its use as an adjunctive therapy for adult patients with drug‐resistant epilepsy (DRE). Methods: Following PRISMA guidelines, PubMed and Ovid MEDLINE databases were searched until January 2025 for English‐language studies reporting pre‐ and post‐rTMS seizure frequencies and detailed protocols in adult patients with DRE. Random‐effects meta‐analyses pooled standardized mean differences in weekly seizure frequency at immediate, 4‐week, and 8‐week follow‐ups. Risk of bias was assessed using the Joanna Briggs Institute (JBI) critical appraisal tools, and evidence certainty was graded using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) and Oxford Centre for Evidence‐Based Medicine (OCEBM) frameworks. Results: 12 studies involving 150 participants were included, with seven contributing to the meta‐analysis. Meta‐analysis demonstrated a small but statistically significant reduction in seizure frequency at 4 and 8 weeks following rTMS (pooled SMD −.49 [95% CI −.98 to −.01, p = .46] and −.19 [95% CI −.35 to −.02, p = .91]), with insignificant heterogeneity ( I 2 = 0%). In contrast, no statistically significant difference was observed immediately after rTMS (pooled SMD .19 [95% CI −1.69 to 1.31, p = .38]). Common adverse effects included headaches (14%–33%) and hearing problems (9%–14%). Quality of life improved significantly in two of three studies, and one study reported depression improvement in 67% of participants. Risk of bias was low in three studies, moderate in five, and high in four. Conclusion: rTMS use as adjunctive therapy for DRE demonstrated moderate (GRADE level 2) and low‐quality (OCEBM level 3) evidence. rTMS was associated with modest reductions in seizure frequency in selected populations. However, effect sizes were small and heterogeneous. Larger, prospective, multicenter studies are needed to further evaluate its efficacy. Registration: International Prospective Register of Systematic Reviews (PROSPERO) (ID #CRD42024553998).


  • Open Access

    The use of cannabidiol as adjunctive therapy in adult patients with drug-resistant epilepsy: a systematic review and meta-analysis

    by Marjorie Jia Yi Ong, Muhammad Samir Haziq Abd Rahman, Vanessa Lin Lin Lee, Kong Heng Lee, Carmen Jia Yinn Chang, Ching Soong Khoo, Rozita Hod, Hui Jan Tan, Eugen Trinka

    Background: Highly purified cannabidiol (CBD), recently approved for various neurological disorders, is explored as a potential therapeutic avenue for drug-resistant epilepsy (DRE) among adult people with epilepsy (PWE) in this systematic review and meta-analysis. Objectives: To conduct an extensive literature review and meta-analysis of CBD use for DRE in adult PWE. Design: Systematic review and meta-analysis. Data sources and methods: We conducted a systematic review of the literature according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and two electronic resources; we searched Ovid MEDLINE and Scopus using appropriate keywords until August 2023. Data were presented as standardized mean difference (SMD) and odds ratio with confidence interval (CI) via random effect. We appraised the risk of bias of the included studies using the Joanna Briggs Institute critical appraisal tool while their strength of evidence with the Oxford Centre for Evidence-Based Medicine (OCEBM) and Grading of Recommendations Assessment Development and Education (GRADE) Levels of Evidence. Results: We identified 16 studies, 3 of which were randomized controlled trials and 3 prospective cohort studies, while the rest were expanded access programs, deriving a total of 668 participants receiving CBD for seizure control. CBD was used concomitantly with antiseizure medications in all studies. There was a reduction in seizures in the group receiving CBD therapy compared to the placebo group [SMD: −1.50, 95% CI (−3.47, 0.47)], though this did not reach statistical significance. Conclusion: The evidence on CBD use in adult patients with DRE demonstrates a moderate level of certainty according to GRADE level and OCEBM level 2. Further prospective studies involving multiple centers are encouraged to study both the efficacy and safety of CBD in adult patients with DRE. Trial registration: International Prospective Register of Systematic Reviews (PROSPERO) 2023 CRD42023449955.